While it is likely that the Trump administration's proposed International Pricing Index would lower drug prices in the United States by at least a little, there are a number of potential unintended consequences that aren't clear at this point, said Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy; director of the Healthcare Markets and Regulation Lab in the Department of Health Care Policy at Harvard Medical School; and co-editor-in-chief of The American Journal of Managed Care®.
While it is likely that the Trump administration's proposed International Pricing Index would lower drug prices in the United States by at least a little, there are a number of potential unintended consequences that aren't clear at this point, said Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy; director of the Healthcare Markets and Regulation Lab in the Department of Health Care Policy at Harvard Medical School; and co-editor-in-chief of The American Journal of Managed Care®.
Transcript
The Trump administration recently announced the International Pricing Index. Is this a policy you believe could successfully reduce drug prices in Medicare?
I’ll answer it first directly and then I’ll talk a little more broad about the policy. It is certainly the case that it’s a policy which could lower drug prices. There’s a question of how much. Usually what happens in policies like that is the high-paying country, in this case the United States, would end up paying somewhat less, but the point here to understand is the low-paying countries would pay somewhat more. The question is: where in the middle would we end up? And then there’s a whole slew of potential unintended consequences, which I think we can enumerate, but we may not be able to quantify.
A good example would be what it does to innovation in pharmaceutical areas? How it influences other types of contracts that are going on in the United States outside of Medicare? As there’s a whole bunch of moving pieces that change in response to any particular policy change. What it does to patient access? What it does to drug shortages? There’s a whole bunch of questions that arise in these types of policies. In fact, there’s even broader ones related to the politics between us and other countries. How do the Europeans react now that there will be upward pressure on their prices if there’s somewhat downward pressure on ours? I think certainly, it could lower our drug prices some extent, but it’s not a simple, quick fix to the problem.
And what we have to understand, I think broadly, is we’re in an era where cost containment has become so important, that one way or another we’re going to control spending. And the challenge is to find the way to do that which is the least deleterious, and I am not sure, in this particular case, how that balance plays out. But we shouldn’t think of this as "might it work" or "might it not," which is obviously a reasonable question, but relative to what? It’s not clear that the status quo is the right alternative. So we’ll see what happens. I wish I could give you something more insightful.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More